[go: up one dir, main page]

PE20210115A1 - Anticuerpos anti-tau y uso de los mismos - Google Patents

Anticuerpos anti-tau y uso de los mismos

Info

Publication number
PE20210115A1
PE20210115A1 PE2020000397A PE2020000397A PE20210115A1 PE 20210115 A1 PE20210115 A1 PE 20210115A1 PE 2020000397 A PE2020000397 A PE 2020000397A PE 2020000397 A PE2020000397 A PE 2020000397A PE 20210115 A1 PE20210115 A1 PE 20210115A1
Authority
PE
Peru
Prior art keywords
seq
complementarity determining
determining region
chain complementarity
heavy chain
Prior art date
Application number
PE2020000397A
Other languages
English (en)
Inventor
Malcolm Ian Roberts
James Martin Staddon
Silva Hettihewage Alfred Rohan De
Jared Spidel
Hirofumi Aoyagi
Shigeru Akasofu
Yutaka Hashizume
Kishan Agarwala
Original Assignee
Eisai Randd Man Co Ltd
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Randd Man Co Ltd, Ucl Business Ltd filed Critical Eisai Randd Man Co Ltd
Publication of PE20210115A1 publication Critical patent/PE20210115A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a anticuerpos que enlazan especificamente al receptor Tau humano y metodos para usar los mismos, en donde dichos anticuerpos comprenden una region determinadora de complementariedad de cadena pesada 1 (HCDR1), una region determinadora de complementariedad de cadena pesada 2 (HCDR2), y una region determinadora de complementariedad de cadena pesada 3 (HCDR3) de SEQ ID NO: 196 y una region determinadora de complementariedad de cadena ligera 1 (LCDR1), una region determinadora de complementariedad de cadena ligera 2 (LCDR2), y una region determinadora de complementariedad de cadena ligera 3 (LCDR3) de SEQ ID NO: 411; ademas presenta una HCDR1, una HCDR2, y una HCDR3 de SEQ ID NO: 268 o SEQ ID NO: 402 y una LCDR1, una LCDR2, y una LCDR3 de SEQ ID NO: 465 o SEQ ID NO: 572. Estos compuestos son utiles para tratar tauopatias como la enfermedad de Alzheimer, demencia frontotemporal, o paralisis supranuclear progresiva
PE2020000397A 2017-10-16 2018-10-16 Anticuerpos anti-tau y uso de los mismos PE20210115A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762572910P 2017-10-16 2017-10-16
US201762577011P 2017-10-25 2017-10-25
US201862697034P 2018-07-12 2018-07-12
PCT/IB2018/058024 WO2019077500A1 (en) 2017-10-16 2018-10-16 ANTI-WATER ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
PE20210115A1 true PE20210115A1 (es) 2021-01-19

Family

ID=64100697

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2020000397A PE20210115A1 (es) 2017-10-16 2018-10-16 Anticuerpos anti-tau y uso de los mismos
PE2021000519A PE20212088A1 (es) 2017-10-16 2018-10-16 Anticuerpos anti-tau y uso de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2021000519A PE20212088A1 (es) 2017-10-16 2018-10-16 Anticuerpos anti-tau y uso de los mismos

Country Status (21)

Country Link
US (4) US10829547B2 (es)
EP (1) EP3697814A1 (es)
JP (2) JP6851549B2 (es)
KR (2) KR102225178B1 (es)
CN (1) CN111630064B (es)
AU (1) AU2018352308B2 (es)
BR (1) BR112020007536A2 (es)
CA (1) CA3077247A1 (es)
CL (3) CL2020001003A1 (es)
CO (1) CO2020005981A2 (es)
IL (2) IL273832B (es)
JO (1) JOP20200074A1 (es)
MA (1) MA50397A (es)
MX (1) MX2020003857A (es)
PE (2) PE20210115A1 (es)
PH (2) PH12020551216A1 (es)
SG (1) SG11202003392VA (es)
TW (3) TWI750419B (es)
UA (1) UA129617C2 (es)
WO (1) WO2019077500A1 (es)
ZA (1) ZA202001548B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689904A1 (en) 2013-03-13 2020-08-05 Prothena Biosciences Limited Tau immunotherapy
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
US10829547B2 (en) 2017-10-16 2020-11-10 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
US12060434B2 (en) * 2020-02-25 2024-08-13 Gensun Biopharma Inc. Trispecific T cell engagers
US20220064271A1 (en) * 2020-09-01 2022-03-03 Washington University Methods for treating tauopathies
US20230406914A1 (en) * 2020-10-02 2023-12-21 Eli Lilly And Company Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content
JP2024525559A (ja) 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
EP4426336A1 (en) 2021-11-03 2024-09-11 Eisai R&D Management Co., Ltd. Anti-tau antibody compositions, dosage forms, and methods
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023111618A1 (en) 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
AU2022410770A1 (en) 2021-12-17 2024-06-13 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
AU2022439338A1 (en) 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
WO2024118665A1 (en) 2022-11-28 2024-06-06 Eisai R&D Management Co., Ltd. Methods of treatment using a tau pet level
WO2024254542A1 (en) 2023-06-09 2024-12-12 Eisai R&D Management Co., Ltd. Methods of treatment using an anti-abeta protofibril antibody
TW202518027A (zh) 2023-07-15 2025-05-01 日商衛材R&D企管股份有限公司 抗微生物肽
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
WO2025198916A1 (en) * 2024-03-16 2025-09-25 Abbvie Inc. Anti-tau antibodies

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0820452A2 (pt) 2007-12-18 2015-06-16 Bioalliance Cv Anticorpos que reconhecendo um epítopo contendo um carboidrato em cd-43 e cea expressos em células cancerosas e métodos de uso dos mesmos.
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
CN103339146B (zh) 2010-10-11 2017-09-01 比奥根国际神经科学公司 人抗tau抗体
JP2014509514A (ja) 2011-03-11 2014-04-21 ラモット アット テルアヴィブ ユニヴァーシティ リミテッド 神経変性タウオパシーを治療するための方法
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
UA115657C2 (uk) 2011-09-19 2017-12-11 Аксон Ньюросайєнс Сє Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
EP3578567A1 (en) 2011-12-20 2019-12-11 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
KR102132041B1 (ko) * 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
HRP20192267T1 (hr) 2012-05-31 2020-03-20 Osaka City University Terapeutski agens ili profilaktički agens za demenciju
MX359555B (es) * 2012-07-03 2018-10-02 Univ Washington Anticuerpos para tau.
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
EP2906596B1 (en) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014089104A1 (en) 2012-12-03 2014-06-12 Washington University Method for detection of aggregates in biological samples
EP3792278A3 (en) 2012-12-21 2021-05-26 Biogen MA Inc. Human anti-tau antibodies
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
EP3689904A1 (en) 2013-03-13 2020-08-05 Prothena Biosciences Limited Tau immunotherapy
EP2970452A2 (en) 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
BR112015030356A2 (pt) 2013-06-10 2017-12-05 Ipierian Inc métodos de tratamento de uma taupatia
GB201312226D0 (en) 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
MX2016007208A (es) 2013-12-20 2016-07-21 Hoffmann La Roche Anticuerpos anti-tau(ps422) humanizados y metodos de uso.
JP6341274B2 (ja) 2014-05-07 2018-06-13 株式会社村田製作所 弾性表面波装置
SG11201610446XA (en) * 2014-06-26 2017-01-27 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
DE102014013571A1 (de) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
RS61431B1 (sr) * 2014-11-19 2021-03-31 Axon Neuroscience Se Humanizovana antitela na tau u alchajmerovoj bolesti
AU2015353585A1 (en) 2014-11-25 2017-06-01 Abbott Diabetes Care Inc. Analyte monitoring systems and related test and monitoring methods
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2016137950A1 (en) 2015-02-24 2016-09-01 Rpeptide, Llc Anti-tau antibodies
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
MX2017015817A (es) 2015-07-06 2018-04-10 Ucb Biopharma Sprl Anticuerpos de union a tau.
EA036821B1 (ru) 2015-07-06 2020-12-23 Юсб Биофарма Срл Тау-связывающие антитела
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US9704904B2 (en) * 2015-08-27 2017-07-11 Taiwan Semiconductor Manufacturing Company, Ltd. Deep trench isolation structures and methods of forming same
WO2017062496A2 (en) 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
KR102750101B1 (ko) 2016-05-02 2025-01-03 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
MY197836A (en) 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
PE20200695A1 (es) * 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
US10829547B2 (en) * 2017-10-16 2020-11-10 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof

Also Published As

Publication number Publication date
CN111630064B (zh) 2023-06-27
US20190112365A1 (en) 2019-04-18
IL290783A (en) 2022-04-01
JP2020536534A (ja) 2020-12-17
US10358485B2 (en) 2019-07-23
TWI853617B (zh) 2024-08-21
TWI809562B (zh) 2023-07-21
US20190112364A1 (en) 2019-04-18
EP3697814A1 (en) 2020-08-26
TWI750419B (zh) 2021-12-21
JOP20200074A1 (ar) 2020-04-30
US10829547B2 (en) 2020-11-10
RU2020115817A (ru) 2021-11-18
TW202207985A (zh) 2022-03-01
UA129617C2 (uk) 2025-06-18
CN111630064A (zh) 2020-09-04
US11578120B2 (en) 2023-02-14
PH12020550243A1 (en) 2021-02-15
IL273832B (en) 2022-06-01
CA3077247A1 (en) 2019-04-25
AU2018352308A1 (en) 2020-03-19
WO2019077500A1 (en) 2019-04-25
CL2021000516A1 (es) 2021-09-24
CO2020005981A2 (es) 2020-07-31
ZA202001548B (en) 2021-10-27
US20240034777A1 (en) 2024-02-01
IL273832A (en) 2020-05-31
KR20200051035A (ko) 2020-05-12
JP6851549B2 (ja) 2021-03-31
RU2020115817A3 (es) 2022-04-08
KR20200058480A (ko) 2020-05-27
MA50397A (fr) 2020-08-26
JP7223794B2 (ja) 2023-02-16
CL2021000517A1 (es) 2021-09-24
KR102225178B1 (ko) 2021-03-10
TW201927817A (zh) 2019-07-16
CL2020001003A1 (es) 2020-10-02
AU2018352308B2 (en) 2025-06-05
JP2021097698A (ja) 2021-07-01
US20210024622A1 (en) 2021-01-28
SG11202003392VA (en) 2020-05-28
TW202340244A (zh) 2023-10-16
BR112020007536A2 (pt) 2020-09-29
PE20212088A1 (es) 2021-11-04
PH12020551216A1 (en) 2024-06-24
MX2020003857A (es) 2021-01-08

Similar Documents

Publication Publication Date Title
PE20210115A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20210180A1 (es) Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
CL2018001177A1 (es) Anticuerpos vinculados especificamente a pd-1 y sus usos.
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
PE20180041A1 (es) Anticuerpos dirigidos a la proteina morfogenetica osea (bmp9) y metodos a partir de estos
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
CU24498B1 (es) Anticuerpos de factor xi
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
PE20191045A1 (es) Anticuerpos anti-il-33 y usos de los mismos
NZ740221A (en) St2l antagonists and methods of use
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PH12016501366A1 (en) Novel anti-baff antibodies
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
EA201791590A1 (ru) Антитела к tau и их применение